NOVACCESS GLOBAL INC News

NOVACCESS GLOBAL INC | 10-Q: Quarterly report

SEC announcementMay 15 07:55 ET · Announcements

NovAccess Global Advisory on Annual Meeting of Shareholders

CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its A

AccesswireMay 7 11:25 ET

NovAccess Global Announces New License to Advance Its Immunotherapy Platform

CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous syste

AccesswireApr 30 09:00 ET

NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders

CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de

AccesswireMar 1 09:00 ET

NovAccess Global Jumps on Announcing $10.7 Million Financing

Seeking AlphaJan 2 10:54 ET

NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit

Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th In

newsfileDec 1, 2023 16:51 ET

NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board

CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app

AccesswireNov 10, 2023 09:00 ET

NovAccess Global Partners With BCN Biosciences to Expand Immunotherapy Platform

Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS TumorsPotential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology MarketCLEVELAND, OH /

AccesswireJul 27, 2023 08:30 ET

NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day

CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv

AccesswireJul 13, 2023 08:30 ET

NovAccess Global Partners With CKN Ventures to Expand Its New AI-driven Precision Medicine Division

CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a

AccesswireJun 16, 2023 12:40 ET

NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies

CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Prec

AccesswireJun 1, 2023 08:40 ET

NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements

Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain TumorsRecent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at

AccesswireMay 11, 2023 09:00 ET

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardCLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developi

AccesswireMar 15, 2023 09:03 ET

Short Interest in NovAccess Global Inc. (OTCMKTS:XSNX) Declines By 52.6%

NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 3,600 shares, a decline of 52.6% fro

kopsourceMar 10, 2023 09:56 ET

NovAccess Global to Present at World Orphan Drug Congress

CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dw

AccesswireFeb 16, 2023 09:02 ET

NovAccess Global Inc. (OTCMKTS:XSNX) Sees Significant Decrease in Short Interest

NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 3,900 shares, a decline of 25.0% from

Defense WorldFeb 14, 2023 03:32 ET

Short Interest in NovAccess Global Inc. (OTCMKTS:XSNX) Decreases By 25.0%

NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 3,900 shares, a drop of

Financial News LiveFeb 12, 2023 12:21 ET

NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress

Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his ContributionsCLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical com

AccesswireFeb 3, 2023 09:02 ET

NovAccess Global Inc. (OTCMKTS:XSNX) Sees Significant Drop in Short Interest

NovAccess Global Inc. (OTCMKTS:XSNX – Get Rating) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 5,800 shares, a decreas

Defense WorldNov 30, 2022 01:11 ET

NovAccess Global Announces Initial Fireside Chat With Glioblastoma Patient Advocate

Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support NetworksCLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomed

AccesswireNov 22, 2022 08:05 ET